IDEAYA Biosciences, Inc.
NASDAQ:IDYA
34.75 (USD) • At close September 18, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
| Revenue
| 23.385 | 50.931 | 27.941 | 19.538 | 0 | 0 | 0 |
| Cost of Revenue
| 4.008 | 2.101 | 1.725 | 39.698 | 1.245 | 0.886 | 0.391 |
| Gross Profit
| 19.377 | 48.83 | 26.216 | -20.16 | -1.245 | -0.886 | -0.391 |
| Gross Profit Ratio
| 0.829 | 0.959 | 0.938 | -1.032 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 129.508 | 89.536 | 58.158 | 39.698 | 34.319 | 31.749 | 12.384 |
| General & Administrative Expenses
| 28.306 | 23.897 | 20.051 | 15.184 | 9.952 | 4.668 | 2.054 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 28.306 | 23.897 | 20.051 | 15.184 | 9.952 | 4.668 | 2.054 |
| Other Expenses
| 0 | 0 | 0 | 0 | 0.008 | 0.077 | 2.426 |
| Operating Expenses
| 157.814 | 113.433 | 78.209 | 54.882 | 44.271 | 36.417 | 14.438 |
| Operating Income
| -134.429 | -62.502 | -50.268 | -35.344 | -44.271 | -36.417 | -14.438 |
| Operating Income Ratio
| -5.749 | -1.227 | -1.799 | -1.809 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| 21.468 | 3.847 | 0.506 | 0.849 | 2.296 | 0.077 | 2.426 |
| Income Before Tax
| -112.961 | -58.655 | -49.762 | -34.495 | -41.975 | -34.346 | -11.862 |
| Income Before Tax Ratio
| -4.83 | -1.152 | -1.781 | -1.766 | 0 | 0 | 0 |
| Income Tax Expense
| 3.84 | -3.847 | -2.231 | -2.23 | -3.533 | 2.071 | -0.15 |
| Net Income
| -112.961 | -54.808 | -47.531 | -32.265 | -38.442 | -34.346 | -11.862 |
| Net Income Ratio
| -4.83 | -1.076 | -1.701 | -1.651 | 0 | 0 | 0 |
| EPS
| -1.96 | -1.32 | -1.35 | -1.31 | -1.9 | -2.41 | -0.83 |
| EPS Diluted
| -1.96 | -1.32 | -1.35 | -1.31 | -1.9 | -2.41 | -0.83 |
| EBITDA
| -130.421 | -62.502 | -50.268 | -35.344 | -44.271 | -35.531 | -14.047 |
| EBITDA Ratio
| -5.577 | -1.227 | -1.799 | -1.809 | 0 | 0 | 0 |